|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial显示文摘 | Shen J Wenger N Glaspy J | 2000 | JAMA2000，284，21： | 1 |
| 2 | Whole-body 18F-FDG PET imaging {or staging of Hodgkin's disease and lymphoma显示文摘 | Hoh CK Glaspy J Rosen P | 1997 | J Nucl Med1997，38，3： | 1 |
| 3 | Results of a multicenter, randomized, double-blind,dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignanl melanoma 显示文摘 | Glaspy J Atkins MB Richards JM | 2009 | Cancer2009，115，22： | 1 |
| 4 | RIBBON-l: randomized, double-blind, placebo-controlled, phase III trial of chemother- apy with or without bevacizumab for first-line treatment of hu- man epidermal growth factor receptor 2-negative, locally recur- rent or metastatic breast cancer显示文摘 | Robert NJ Di e ras V Glaspy J | 2011 | J Clin Oncol2011，29，10： | 1 |
| 5 | Phase Ⅱ study of two dose schedules of CERA ( continuous erythropoietin receptor activator ) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy显示文摘 | Hirsh V Glaspy J Mainwaring P Manegold C Ramlau R Eid JE | 2007 | Trials2007，8，： | 1 |
| 6 | Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum-and nonplatinumbased chemotherapy-a retrospective subanalysis of two large,community-based trials显示文摘 | Glaspy J Degos L Dicato M | 2002 | Oncologist2002，7，2： | 1 |
| 7 | Current developments in cancer vaccines and cellular immunotherapy显示文摘 | Ribes A Butterfield L H Glaspy J A | 2003 | J Clinic Oncol2003，21，12： | 1 |
| 8 | Role of Iron in optimizing responses of anemic Cancer patients to erythropoietin 显示文摘 | Glaspy J Cavill I | 1999 | Oncology1999，13，4： | 1 |
| 9 | Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment显示文摘 | Chang HR Glaspy J Allison MA | 2010 | Cancer2010，116，18： | 1 |
| 10 | RIBBON-1 : ran- domized, double-blind, placebo-controlled, phase III tri- al of chemotherapy with or without bevacizumab for first- line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer 显示文摘 | Robert N J Dieras V Glaspy J | 2011 | J Clin Oncol2011，29，10： | 1 |
| 11 | Kirschner wire embolization to the heart:an unusual cause of pericardial tamponade显示文摘 | Goodsett J R Pahl A C Glaspy J N | 1999 | Chest1999，115，： | 1 |
| 12 | Biology and clinical potential of stem-cell factor 显示文摘 | Glaspy J Davis MW Parker WR | 1996 | Cancer Chemother Pharmacol1996，38，： | 1 |
| 13 | RIBBON- 1: randomized, double-blind, placebo-controlled, phase !I1 trial of chemotherapy with or without bevacizumab for first- line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer显示文摘 | ROBERT NJ DIERAS V GLASPY J | 2011 | J Clin Oncol2011，29，10： | 1 |
| 14 | Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia 显示文摘 | Crawford J Glaspy JA Stoller RG | 2005 | Support Cancer Ther2005，3，1： | 1 |
| 15 | Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma 显示文摘 | Hoh C K Glaspy J Rosen P | 1997 | J Nucl Med1997，38，3： | 1 |
| 16 | Role of iron in optimizing responses of anemic cancer patients to erythropoietin显示文摘 | Glaspy J Cavill I | 1999 | Oncology1999，13，4： | 1 |
| 17 | Role of iron in optimizing responses of anemic cancer patients to erythropoietin显示文摘 | Glaspy J Cavill I | 1999 | Oncology1999，13，4： | 1 |
| 18 | Role of iron in optimizing responses of anemic cancer patients to erythropoietin显示文摘 | Glaspy J Cavill I | 1999 | Oncology1999，13，4： | 1 |
| 19 | Differential re- sponse of triple-negative breast cancer to a docetaxel and carbopl- atin-based neoadjuvant treatment显示文摘 | CHANG H R GLASPY J ALLISON M A | 2010 | Cancer2010，116，18： | 1 |
| 20 | Role of iron in optimizing responses of anemic canser patients to erythropoietin显示文摘 | Glaspy J Cavill L | 1999 | Oncology1999，46，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员